In our study, patients were not directly treated with beta-blockers; however, significantly better clinical outcomes were observed in EGFR-mutant NSCLC patients who were already receiving beta-blockers for cardiovascular indications. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.